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A TELEPHONE REMINDER TO ENHANCE ADHERENCE TO INTERVENTIONS IN 1 




The impact of reduced adherence in randomized clinical trials is well documented in the 6 
literature. Non-adherence can negatively affect the trial sample size and estimation of the 7 
treatment effect. This study aims to evaluate the effects of a telephone call reminder on the 8 
adherence rates of participants to interventions in a cardiovascular randomized trial. This is a 9 
Study within a Trial (SWAT). The host trial is evaluating the effectiveness of a multidisciplinary 10 
16-week cardiovascular disease prevention program on risk factor profile among patients with 11 
carotid artery stenosis. Simultaneously, this SWAT will evaluate the effectiveness of telephone 12 
call reminders on the participants’ adherence to the host trial intervention. The primary 13 
outcome is adherence to the protocol of the host trial.. Secondary outcomes are level of 14 
adherence, number of dropouts, and time to drop out from the host trial. 15 
Keywords  16 
Patient Compliance; Randomized Controlled Trial; Reminder Systems; Study within a Trial 17 
(SWAT); Treatment Adherence and Compliance. 18 
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The All-Ireland Hub for Trials Methodology Research, in collaboration with the Medical 22 
Research Council Network of Hubs in the United Kingdom, have developed the Study Within 23 
A Trial (SWAT) program, to provide studies that would investigate the effects of different 24 
methods of designing, conducting, following-up, analyzing, and interpreting evaluations of 25 
health care, within clinical trials.(1-3) 26 
Explanatory trials where the focus is on measuring the efficacy of an intervention in ideal 27 
conditions, consider adherence to the trial intervention as an integral part of the trial 28 
methodology, and accordingly strict treatment fidelity monitoring measures are put in 29 
place.(4) Conversely, pragmatic clinical trials seek to measure the effectiveness of an 30 
intervention in routine clinical practice environments, and more often than not, adherence to 31 
the intervention being evaluated is not considered.(5, 6) Therefore, adherence in pragmatic 32 
clinical trials, like the host trial in this SWAT, presents a challenge.(7, 8) 33 
The World Health Organization (WHO) defines adherence as the extent to which a trial 34 
participant’s behavior corresponds with the trial protocol in terms of taking medications as 35 
prescribed, attending clinical appointments, and/or executing lifestyle modification 36 
interventions as required.(9, 10) Non-adherence has been well recognized for years to be a 37 
common issue that significantly impacts clinical outcomes and health care costs.(11-13) Poor 38 
adherence is particularly challenging in cardiovascular trials, which mostly aim to manage risk 39 
factors and improve cardiovascular disease prevention.(12, 14) While accepting that routine 40 
clinical cardiovascular secondary prevention practice also suffers from low adherence rates, 41 
yet reduced adherence in cardiovascular clinical trials can have a negative effect on the trial 42 
sample size and estimation of the treatment effects.(15, 16)  43 
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According to a recent report from the Non-adherence Academic Research Consortium 44 
(NARC),(12) the collection of non-adherence data varies substantially among cardiovascular 45 
randomized trials. Even where collected, this data is rarely included in the statistical analysis 46 
to test the reliability of the effect on the primary outcome(s). The imprecision introduced by 47 
the inconsistent assessment of non-adherence in clinical trials might confound the estimate 48 
of the calculated efficacy of the study intervention.(12, 17) Hence, clinical trials may not 49 
accurately answer the scientific question presented by researchers or regulators, who seek an 50 
accurate evaluation of the true efficacy and safety of treatment or interventions. Therefore, 51 
there is a need to evaluate methods used to improve adherence in this area of research.(17) 52 
This study is a SWAT. The host trial is evaluating the effectiveness of an intensive lifestyle 53 
modification program in controlling risk factors and preventing stroke and cardiac events in 54 
patients with asymptomatic carotid artery stenosis. Concurrently, the SWAT aims to evaluate 55 
the effectiveness of telephone call reminders on participants’ adherence within the host trial. 56 
Design for the SWAT  57 
Background 58 
A great deal of effort is often expended in recruiting participants to randomized trials.(18)  59 
Following the challenge of recruiting the required number of participants, there is the problem 60 
of ensuring that all participants remain in the trial and adhere to the trial intervention as 61 
required.(7, 12) Non-adherence to the trial intervention has serious implications, resulting in 62 
decreasing the statistical power of the study, impacting negatively on the trial outcomes and 63 
increasing the risk of attrition bias due to incomplete data.(15, 16, 19) In addition to the loss 64 
of valuable knowledge, low adherence rates can result in research resource wasting and 65 
increasing the cost of randomized trials.(16, 20) 66 
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A distinction is made between intentional and unintentional non-adherence.(19, 21) 67 
Unintentional non-adherence is a passive process whereby patients fail to adhere to 68 
prescribing instructions through forgetfulness, carelessness, or circumstances out of their 69 
control such as health literacy or cognitive impairment.(19, 21) In contrast, intentional non- 70 
adherence is an active decision on the part of patients, which may be based on perceptions of 71 
symptom reduction, fear of side-effects, fear of addiction, or perceived inefficiency of 72 
treatment.(22, 23) 73 
The issue of non-adherence is particularly problematic in cardiac rehabilitation (CR) trials. 74 
Both intentional and unintentional non-adherence were reported in secondary prevention for 75 
cardiovascular disease.(12, 19, 24) Evidence showed that approximately 31% of patients 76 
reported unintentional non-adherence, while  9% reported intentional non-adherence.(22) 77 
Despite the proven benefits of CR,(25, 26) eligible patients do not always agree to take part in 78 
CR. Of those patients that do agree to participate, many do not adhere to the CR programs as 79 
recommended.(10, 12) A recent meta-analysis that included almost 400,000 patients, 80 
estimated that adherence to secondary prevention of cardiovascular disease is only 57%.(27) 81 
Similarly, an evaluation of lifestyle changes among cardiovascular patients in five European 82 
countries indicated that only 50% of patients modified their lifestyles in accordance with 83 
recommendations.(10, 28) 84 
Furthermore, there is evidence that only 50% of patients adhere to cardioprotective 85 
medications 1 year after commencing treatment. Of those taking the medications, about 50% 86 
follow the treatment sufficiently to gain a therapeutic benefit.(10, 29) This is similar to the 87 
estimated prevalence of poor adherence to cardiovascular prevention and medications as 88 
reported by WHO.(30) 89 
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A Cochrane systematic review evaluating the effectiveness of methods and strategies to 90 
promote patients’ adherence in CR programs(17) demonstrated that there is a need to devise 91 
strategies to improve adherence in such programs and evaluate their effectiveness.(17) 92 
Telephone reminders to non-responders were effective in increasing recruitment to trials.(18) 93 
As yet, this strategy has not been tested to improve adherence to trial interventions. 94 
Telephone reminder intervention could have a greater effect on non-intentional non- 95 
adherence in CR trials. This SWAT aims to assess the effectiveness of telephone reminders on 96 
participants’ adherence within the cardiovascular host trial.  97 
Intervention and comparator 98 
Intervention  99 
Participants who have been recruited and randomized to the intervention arm in the host 100 
randomized control trial will be further randomized for this SWAT. Patients in the intervention 101 
arm of the host trial will attend a 16-week multidisciplinary lifestyle program, which includes 102 
healthy lifestyle changes such as smoking cessation, healthy food choices, increasing physical 103 
activity levels, and management of dyslipidemia, diabetes, and hypertension. The intervention 104 
program of the host trial program will consist of 16 sessions of 2.5 hours each per week. Each 105 
of the weekly sessions will incorporate an individualized meeting between a multidisciplinary 106 
healthcare team (which includes a physiotherapist, dietitian, nurse, and physician) and each 107 
patient. The multidisciplinary team will review the progress of each patient and health goals. 108 
The weekly sessions will also include a one-hour group exercise program and an educational 109 
workshop. 110 
Participants allocated to the intervention arm of this SWAT will receive telephone call 111 
reminders to attend the lifestyle intervention program in the host trial. To ensure 112 
standardization of the SWAT intervention, the telephone reminder is a scripted text, where 113 
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the participant is reminded of their appointment date and time (appendix 1). There will be 16 114 
appointments (one appointment every week) for the lifestyle intervention program in the host 115 
trial. Therefore, the SWAT participants will receive a telephone call reminder every week over 116 
the 16-week of lifestyle intervention program. A telephone call reminder will be received two 117 
business days before each appointment. Up to three calls will be made if the line was busy or 118 
there was no answer. For confidentiality reasons, no messages will be left on voicemail. 119 
Comparator 120 
Participants allocated to the control group in this SWAT will not receive any telephone 121 
reminders. At baseline assessment, patients will be given a schedule of their visits throughout 122 
the intervention period. These patients will have no telephone call reminders before their 123 
appointments. 124 
Method for allocating to intervention or comparator 125 
Patients will be allocated to the telephone reminder intervention or to control group via 126 
sealed randomization envelopes, in an equal ratio of 1:1. The investigator will not be able to 127 
identify which arm each patient will be allocated until the sealed envelope has been opened. 128 
The randomization scheme will be produced using the PROC PLAN® procedure of the SAS® 129 
software package. 130 
  131 
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Primary outcome 132 
• Adherence to the protocol of the host trial.  133 
Secondary outcome 134 
• Level of adherence to the protocol of the host trial. 135 
• Number of dropouts from the host trial. 136 
• Time to dropout from the host trial. 137 
Definition of outcomes 138 
In the context of this study, the primary outcome of adherence is defined as 100% attendance. 139 
The secondary endpoint of level of adherence, is measured as the percentage of attendance 140 
of all allocated visits, within the host trial. 141 
Analysis plan 142 
Analyses will include appropriate descriptive analyses, and between-group comparisons using 143 
SPSS software. The primary analysis is the difference in adherence rate between those 144 
receiving the telephone reminders and those not receiving the reminders. This will be done 145 
using chi-square tests. Odds ratios and 95% confidence intervals will be calculated. The 146 
secondary analysis is time to drop-out. This will be plotted by Kaplan-Meier survival curves 147 
and using the log-rank test to compare the two randomized groups. Cox regression will be 148 
used to adjust for age, gender, treatment allocation in the host clinical trial. Analyses will be 149 
undertaken on an intention-to-treat basis, using two-sided statistical significance at the 5% 150 
level. Data will be presented as proportions and percentages (adherence rate) or as the 151 
median, standard error, and interquartile range (time to response). 152 
  153 
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Possible problems 154 
Ethical approvals for the SWAT and the host trial and have been sought and granted; 155 
therefore, we do not anticipate any ethical issues arising. The SWAT protocol has been 156 
registered in the SWAT Repository of the Northern Ireland Network for Trials Methodology 157 
Research (SWAT number 81). However, there is currently no evidence to support the 158 
effectiveness of telephone reminders to improve adherence in a randomized trial. A priori, we 159 
cannot pre-empt that telephone reminders may have an adverse effect on adherence. 160 
Adherence in this study is presented as a trial methodology issue. However, adherence to the 161 
intervention might also be seen as an issue for the intervention delivery. We argue that this 162 
SWAT is not designed to investigate the outcomes of the host trial intervention. The SWAT 163 
will demonstrate the effect of telephone call reminders on patient adherence rates, which 164 
could be used in clinical trials going forward. Nevertheless, if within the host trial, we do find 165 
that patients randomized to either arm of this SWAT study show improved outcomes within 166 
the intervention arm of the host trial, then we could assess if telephone reminders should be 167 
considered as part of the host intervention delivery into routine care. As such, it could have 168 
further implications on routine clinical practice.  169 
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Appendix 1 260 
Reminder Call Script: 261 
This is [the hospital name/health network name/and study name] at [ the department name], 262 
calling to remind you about an appointment for [patient’s name] on [day and date] at [time] 263 
at [the cardiac rehabilitation center name]. Please arrive 15 minutes prior to your 264 
appointment time to allow the registration process. If you have any questions, do not hesitate 265 
to contact the study investigators on [phone number]. We look forward to welcoming you. 266 
Thank you. 267 
 268 
 269 
